Approved for use through D/731/2006 (MRS)

U.S. Patent and Trademask Office, U.S. DEPARTMENT OF CI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB cont

	Application Number		10646653		
	Filing Date		2003-08-21		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Kusa		usakabe et al.		
	Art Unit		2187		
	Examiner Name	Nguy	ren, Than Vinh		
	Attorney Docket Numb	er	112857-784		

	U.S.PATENTS				Remove						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Name of Patentee or A of cited Document			Pages,Columns,Lines where Relevant Passages or Relev Figures Appear				
	1										
If you wis	h to a	l dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.	_	Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of sited Desument		Releva	,Columns,Line ant Passages o s Appear		
	1										
If you wis	h to a	dd additional U.S. Publi						d button			
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Column where Relevan Passages or R Figures Appea	t elevant	Ti
	1	60-207939	JP			1985-10-19	TOSHIBA CORP.				
	2	06-222980	JP			1994-08-12	DAINIPPON PRIN CO. LTD.	TING			
	3	01-197895	JP			1989-08-09	TOSHIBA CORP.				

Application Number 10646653 Filing Date 2003-08-21 INFORMATION DISCLOSURE First Named Inventor Kusakabe et al STATEMENT BY APPLICANT Art I Init 2187 (Not for submission under 37 CFR 1.99) Examiner Name Nauven Than Vinh Attorney Docket Number 112857-784

1987-12-22

TOSHIBA CORP.

Date Considered

	5	01-194093	JP		1989-08-04	TOSHIBA CORP.		
	6	02-050287	JP		1990-02-20	TOSHIBA CORP.		
	7							
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city ander country where published.							T5	
	1							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document.

If you wish to add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

4 62-295149

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10646653		
Filing Date		2003-08-21		
First Named Inventor	Kusakabe et al.			
Art Unit		2187		
Examiner Name	Nguyen, Than Vinh			
Attorney Docket Number		112857-784		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Thomas C. Basso/	Date (YYYY-MM-DD)	2006-09-11
Name/Print	Thomas C. Basso	Registration Number	46541

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenant Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via yet of sciences, subject to the limitations of 37 CFR 1.14, as a routine use, to the public of the record via self or in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.